Petros Pharmaceuticals (NASDAQ:PTPI) Trading Down 2.1%

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) shares traded down 2.1% during trading on Wednesday . The stock traded as low as $0.64 and last traded at $0.69. 457,077 shares were traded during trading, a decline of 55% from the average session volume of 1,006,999 shares. The stock had previously closed at $0.71.

Petros Pharmaceuticals Stock Down 2.9 %

The firm’s fifty day simple moving average is $1.36 and its 200 day simple moving average is $1.37. The company has a current ratio of 1.89, a quick ratio of 1.74 and a debt-to-equity ratio of 0.57.

Petros Pharmaceuticals (NASDAQ:PTPI) last released its quarterly earnings data on Monday, April 1st. The company reported ($2.17) EPS for the quarter. Petros Pharmaceuticals had a negative net margin of 181.87% and a negative return on equity of 68.90%. The company had revenue of ($0.36) million for the quarter.

Institutional Trading of Petros Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC purchased a new stake in shares of Petros Pharmaceuticals during the 2nd quarter valued at about $34,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Petros Pharmaceuticals during the 2nd quarter valued at about $47,000. Virtu Financial LLC purchased a new stake in shares of Petros Pharmaceuticals during the 4th quarter valued at about $35,000. Vanguard Group Inc. raised its position in shares of Petros Pharmaceuticals by 114.8% during the 3rd quarter. Vanguard Group Inc. now owns 255,914 shares of the company’s stock valued at $131,000 after buying an additional 136,773 shares in the last quarter. Finally, BlackRock Inc. raised its position in shares of Petros Pharmaceuticals by 880.2% during the 1st quarter. BlackRock Inc. now owns 191,715 shares of the company’s stock valued at $300,000 after buying an additional 172,156 shares in the last quarter. 12.34% of the stock is currently owned by hedge funds and other institutional investors.

Petros Pharmaceuticals Company Profile

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).